Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Eli Lilly goes direct-to-consumer on weight loss drugs: What patients and investors need to know
09:17am, Thursday, 04'th Jan 2024
Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss news of Eli Lilly's launch of 'LillyDirect', an online direct-to-consumer pharmacy where patients can get the company's obe
Eli Lilly launches online direct-to-consumer pharmacy to help patients get weight loss drugs
08:32am, Thursday, 04'th Jan 2024
CNBC's Bertha Coombs joins 'Squawk Box' with the latest news.
Eli Lilly launches digital health services for patients with obesity, migraine and diabetes
07:57am, Thursday, 04'th Jan 2024
Eli Lilly & Co. LLY, +4.31% on Thursday announced the launch of digital health services for U.S. patients with obesity, migraine and diabetes, saying its new LillyDirect platform will offer access to
Lilly says it stands against cosmetic use of its weight-loss drugs
07:54am, Thursday, 04'th Jan 2024
Eli Lilly and Co said on Thursday it does not promote the use of its obesity and diabetes drugs Mounjaro and Zepbound outside of their approved purposes, and said it stands against their use for "cosm
Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option?
05:00am, Thursday, 04'th Jan 2024
Eli Lilly is a major player in the billion-dollar weight loss drug market. Demand for these types of drugs has climbed -- and could continue to soar in the coming years.
BioPharma stocks face a potentially rocky 2024, analysts say
04:45pm, Wednesday, 03'rd Jan 2024
After a difficult 2023, biopharma investors won't necessarily have it any easier in 2024, analysts at UBS argued in a note to clients on Tuesday. “BioPharma investors will be happy to shut the doo
Why Eli Lilly Stock Is Jumping Today While the Overall Market Is Slumping
12:20pm, Wednesday, 03'rd Jan 2024
Early data points to Lilly's weight-loss drug Zepbound taking market share away from Ozempic and Wegovy. However, Novo Nordisk could still top Lilly in sales gains this year.
Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold
11:08am, Wednesday, 03'rd Jan 2024
Eli Lilly's valuation sets a high bar for the stock. Its rival in the obesity space is a better deal and could be a better business.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:31am, Wednesday, 03'rd Jan 2024
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
09:46am, Tuesday, 02'nd Jan 2024
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
06:12am, Tuesday, 02'nd Jan 2024
Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company is
2024's Power Players: 7 Stocks Racing to a Trillion Valuation
08:56am, Monday, 01'st Jan 2024
As it stands now, six U.S.-listed stocks are in the “trillion dollar club,” or stocks with a market cap of at least $1 trillion. In the coming year, or in the years ahead, which other mega-cap s
Why Eli Lilly Stock Could Start Off 2024 With a Bang
07:15am, Monday, 01'st Jan 2024
The company's early Alzheimer's treatment, donanemab, may soon obtain approval from regulators. It has the potential to generate billions in revenue and may act as another growth catalyst for Lilly.
7 Investments To Avoid In 2024
07:00am, Monday, 01'st Jan 2024
7 Investments To Avoid In 2024
Why Is Eli Lilly Investing Up to $494 Million to Study Squirrel Hibernation?
09:00am, Sunday, 31'st Dec 2023
Eli Lilly is building a foundation for a strong position in the obesity treatment market. Squirrels that hibernate are effective at both gaining and shedding weight.
